Sweden’s MPA on Supporting Adaptive Pathways

[membership level=”0,4″][The content continues for paid members only.] Login or Subscribe [/membership][membership level=”1,5,6,7,8,9,10,11,12″][membership] Sweden’s Medical Products Agency (MPA) has published a 70-page review of how it will support EMA’s adaptive pathways initiative. Included is MPA’s strategy for developing, introducing and monitoring of drug candidates, with a particular focus on Alzheimer’s disease. [For more on EMA’s Adaptive Pathways effort, see IPQ September 9, 2016.]
[/membership]